HUP0301311A2 - N-oxidok mint 4-fenil-piridin-származékok előgyógyszerei, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents

N-oxidok mint 4-fenil-piridin-származékok előgyógyszerei, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0301311A2
HUP0301311A2 HU0301311A HUP0301311A HUP0301311A2 HU P0301311 A2 HUP0301311 A2 HU P0301311A2 HU 0301311 A HU0301311 A HU 0301311A HU P0301311 A HUP0301311 A HU P0301311A HU P0301311 A2 HUP0301311 A2 HU P0301311A2
Authority
HU
Hungary
Prior art keywords
group
lower alkyl
compounds
hydrogen atom
hydrogen
Prior art date
Application number
HU0301311A
Other languages
English (en)
Inventor
Torsten Hoffmann
Sonia Maria Poli
Patrick Schnider
Andrew Sleight
Original Assignee
F. Hoffmann-La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag. filed Critical F. Hoffmann-La Roche Ag.
Publication of HUP0301311A2 publication Critical patent/HUP0301311A2/hu
Publication of HU230316B1 publication Critical patent/HU230316B1/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

A találmány (I) általános képletű vegyületekre[mely képletben Rjelentése hidrogénatom, kis szénatomszámú alkil-, kis szénatomszámúalkoxicsoport, halogénatom vagy trifluor-metil-csoport; R1 jelentésehidrogén- vagy halogénatom; vagy R és R1 a gyűrűszénatomokkal együtt,amelyekhez kapcsolódnak -CH=CH-CH=CH-csoportot képeznek; R2 és R2'jelentése egymástól függetlenül hidrogénatom, halogénatom, trifluor-metil-, kis szénatomszámú alkoxi- vagy cianocsoport; vagy R2 és R2'együtt -CH=CH-CH=CH- csoportot képez, amely adott esetben egy vagy kétkis szénatomszámú alkil- és/vagy kis szénatomszámú alkoxicsoporttalhelyettesítve lehet; R3 és R3' jelentése egymástól függetlenülhidrogénatom, kis szénatomszámú alkil- vagy cikloalkilcsoport; R4 ésR4' jelentése egymástól függetlenül -(CH2)mOR6 vagy kis szénatomszámúalkilcsoport; vagy R4 és R4' a nitrogénatommal együtt, amelyhezkapcsolódik, (A) általános képletű gyűrűs tercier-amino-csoportotképez; R5 jelentése hidrogénatom, hidroxil-, kis szénatomszámú alkil-,kis szénatomszámú alkoxicsoport, -(CH2)mQH, -COOR3, -CON(R3)2, -N(R3)CO-kis szénatomszámú alkil- vagy -C(O)R3 csoport; R6 jelentésehidrogénatom, kis szénatomszámú alkil- vagy fenilcsoport; X jelentése-C(O)N(R6)- , -N(R6)C(O)- , -(CH2)mO- vagy -O(CH2)m-; n értéke 0, 1,2, 3 vagy 4; és m értéke 1, 2 vagy 3] és gyógyászatilag alkalmassavaddíciós sóikra és a vegyületek előállítására vonatkozik. Atalálmány kiterjed a vegyületeket tartalmazó gyógyszerkészítményekreis. A fenti vegyületek NK-1 receptorral összefüggő betegségekkezelésénél vagy megelőzésénél előgyógyszerként (prodrug)alkalmazhatók. Ó
HU0301311A 2000-07-14 2001-07-09 N-oxidok, mint 4-fenil-piridin-származékok előgyógyszerei, eljárás és előállításukra és az ezeket tartalmazó gyógyszerkészítmények HU230316B1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00115287 2000-07-14
EP00115287.5 2000-07-14
PCT/EP2001/007850 WO2002006236A1 (en) 2000-07-14 2001-07-09 N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives

Publications (2)

Publication Number Publication Date
HUP0301311A2 true HUP0301311A2 (hu) 2003-08-28
HU230316B1 HU230316B1 (hu) 2016-01-28

Family

ID=8169262

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301311A HU230316B1 (hu) 2000-07-14 2001-07-09 N-oxidok, mint 4-fenil-piridin-származékok előgyógyszerei, eljárás és előállításukra és az ezeket tartalmazó gyógyszerkészítmények

Country Status (39)

Country Link
US (4) US6593472B2 (hu)
EP (1) EP1303490B1 (hu)
JP (1) JP3950044B2 (hu)
KR (1) KR100501608B1 (hu)
CN (1) CN1178917C (hu)
AR (1) AR029717A1 (hu)
AT (1) ATE400556T1 (hu)
AU (1) AU7061901A (hu)
BR (1) BRPI0112475B8 (hu)
CA (1) CA2415890C (hu)
CY (1) CY1108557T1 (hu)
CZ (1) CZ303639B6 (hu)
DE (1) DE60134749D1 (hu)
DK (1) DK1303490T3 (hu)
EC (1) ECSP034431A (hu)
EG (1) EG24968A (hu)
ES (1) ES2309075T3 (hu)
GT (1) GT200100137A (hu)
HK (1) HK1058198A1 (hu)
HR (1) HRP20030003B1 (hu)
HU (1) HU230316B1 (hu)
IL (2) IL153834A0 (hu)
JO (1) JO2372B1 (hu)
MA (1) MA26929A1 (hu)
ME (1) ME01311B (hu)
MX (1) MXPA03000366A (hu)
MY (1) MY154976A (hu)
NO (1) NO324700B1 (hu)
NZ (1) NZ523273A (hu)
PA (1) PA8522001A1 (hu)
PE (1) PE20020272A1 (hu)
PL (1) PL205207B1 (hu)
PT (1) PT1303490E (hu)
RS (1) RS50932B (hu)
RU (1) RU2266284C2 (hu)
SI (1) SI1303490T1 (hu)
UY (1) UY26839A1 (hu)
WO (1) WO2002006236A1 (hu)
ZA (1) ZA200210207B (hu)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2208205T3 (es) * 1999-11-29 2004-06-16 F. Hoffmann-La Roche Ag 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-otolil-piridin-3-il)-isobutiramida.
CZ303639B6 (cs) * 2000-07-14 2013-01-23 F. Hoffmann-La Roche Ag N-Oxid derivátu 4-fenylpyridinu, zpusob jeho prípravy a lécivo s jeho obsahem
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
CA2444395C (en) * 2001-04-23 2010-12-21 F. Hoffmann-La Roche Ag Use of nk-1 receptor antagonists against benign prostatic hyperplasia
CA2530886C (en) * 2003-07-03 2013-05-28 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
CA2572645C (en) 2004-07-06 2011-01-18 F. Hoffmann-La Roche Ag Process for preparing carboxamide derivatives used as intermediates in the synthesis of nk-1 receptor antagonists
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
ES2320590T3 (es) * 2005-03-23 2009-05-25 F. Hoffmann-La Roche Ag Metabolitos para antagonistas nk-1 para emesis.
JP2008280248A (ja) * 2005-11-02 2008-11-20 Eisai R & D Management Co Ltd アルツハイマー型痴呆症治療薬塩酸ドネペジルのプロドラッグ
CN101641099A (zh) 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
US8966414B2 (en) 2009-05-29 2015-02-24 Cypress Semiconductor Corporation Implementing a circuit using an integrated circuit including parametric analog elements
US9858367B1 (en) 2009-08-31 2018-01-02 Cypress Semiconductor Corporation Integrated circuit including parametric analog elements
EP2361090B1 (en) 2009-11-18 2014-05-21 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
CN106974912A (zh) 2011-10-18 2017-07-25 赫尔辛医疗股份公司 奈妥匹坦和帕洛诺司琼的治疗性组合
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
PT3738434T (pt) 2011-12-28 2023-11-13 Global Blood Therapeutics Inc Intermediários para obter compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos
CN111454200A (zh) * 2013-03-15 2020-07-28 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
CA2902711C (en) 2013-03-15 2021-07-06 Global Blood Therapeutics, Inc. Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
EP3067349B1 (en) 2013-11-08 2018-02-28 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US10350098B2 (en) * 2013-12-20 2019-07-16 Volcano Corporation Devices and methods for controlled endoluminal filter deployment
SI3102208T1 (sl) 2014-02-07 2021-07-30 Global Blood Therapeutics, Inc. Kristalinični polimorf proste baze 2-hidroksi-6-((2-(1-izopropil-1H-pirazol-5-IL)piridin-3-IL)metoksi)- benzaldehida
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
CN106588899B (zh) * 2015-10-15 2019-11-15 江苏恒瑞医药股份有限公司 吡啶基取代的6-氧杂螺[4.5]癸烷类衍生物、其制备方法及其在医药上的应用
MA43373A (fr) 2015-12-04 2018-10-10 Global Blood Therapeutics Inc Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
TWI752307B (zh) 2016-05-12 2022-01-11 美商全球血液治療公司 新穎化合物及製造化合物之方法
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US11160809B2 (en) 2017-04-10 2021-11-02 Chase Therapeutics Corporation NK1-antagonist combination and method for treating synucleinopathies
BR112019028034A2 (pt) 2017-06-30 2020-07-07 Chase Therapeutics Corporation composições de antagonista de nk-1 e métodos para uso no tratamento da depressão
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56106286A (en) 1980-01-28 1981-08-24 Nippon Musical Instruments Mfg Electronic musical instrument
EP0103545A3 (en) 1982-09-13 1984-10-03 Arc Technologies Systems, Ltd. Electrode for arc furnaces
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
PL181214B1 (pl) 1993-12-29 2001-06-29 Merck Sharp & Dohme Podstawione związki morfolinowe, sposób ich wytwarzania oraz zawierające je kompozycje farmaceutyczne
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
AR008789A1 (es) * 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
CZ20013046A3 (cs) * 1999-02-24 2002-02-13 F. Hoffmann-La Roche Ag Fenylové a pyridinylové deriváty
ATE277905T1 (de) * 1999-02-24 2004-10-15 Hoffmann La Roche 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
ES2208205T3 (es) * 1999-11-29 2004-06-16 F. Hoffmann-La Roche Ag 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-otolil-piridin-3-il)-isobutiramida.
CZ303639B6 (cs) * 2000-07-14 2013-01-23 F. Hoffmann-La Roche Ag N-Oxid derivátu 4-fenylpyridinu, zpusob jeho prípravy a lécivo s jeho obsahem
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury

Also Published As

Publication number Publication date
RS50932B (sr) 2010-08-31
NO324700B1 (no) 2007-12-03
CN1178917C (zh) 2004-12-08
IL153834A0 (en) 2003-07-31
ECSP034431A (es) 2003-03-10
CZ303639B6 (cs) 2013-01-23
ZA200210207B (en) 2004-03-17
EP1303490A1 (en) 2003-04-23
PE20020272A1 (es) 2002-04-16
IL153834A (en) 2008-11-03
DE60134749D1 (de) 2008-08-21
MXPA03000366A (es) 2003-05-27
US20040014793A1 (en) 2004-01-22
PL365684A1 (en) 2005-01-10
EP1303490B1 (en) 2008-07-09
HRP20030003A2 (en) 2003-02-28
US6747026B2 (en) 2004-06-08
EG24968A (en) 2011-03-14
KR100501608B1 (ko) 2005-07-18
HRP20030003B1 (en) 2011-01-31
US20030149039A1 (en) 2003-08-07
NZ523273A (en) 2004-08-27
ATE400556T1 (de) 2008-07-15
JO2372B1 (en) 2006-12-12
GT200100137A (es) 2002-05-16
YU603A (sh) 2006-01-16
MY154976A (en) 2015-08-28
WO2002006236A1 (en) 2002-01-24
PT1303490E (pt) 2008-09-04
BR0112475A (pt) 2003-07-29
RU2266284C2 (ru) 2005-12-20
UY26839A1 (es) 2002-01-31
US6806370B2 (en) 2004-10-19
SI1303490T1 (sl) 2008-10-31
BRPI0112475B8 (pt) 2021-05-25
KR20030015387A (ko) 2003-02-20
NO20030154D0 (no) 2003-01-13
US6897226B2 (en) 2005-05-24
BR0112475B1 (pt) 2013-10-15
HK1058198A1 (en) 2004-05-07
NO20030154L (no) 2003-01-13
AU7061901A (en) 2002-01-30
HU230316B1 (hu) 2016-01-28
JP2004504301A (ja) 2004-02-12
DK1303490T3 (da) 2008-08-25
MA26929A1 (fr) 2004-12-20
CA2415890A1 (en) 2002-01-24
JP3950044B2 (ja) 2007-07-25
ME01311B (me) 2013-12-20
CY1108557T1 (el) 2014-04-09
ES2309075T3 (es) 2008-12-16
US6593472B2 (en) 2003-07-15
US20040048901A1 (en) 2004-03-11
AR029717A1 (es) 2003-07-10
US20020045642A1 (en) 2002-04-18
CN1441782A (zh) 2003-09-10
PA8522001A1 (es) 2002-04-25
PL205207B1 (pl) 2010-03-31
CA2415890C (en) 2009-04-07

Similar Documents

Publication Publication Date Title
HUP0301311A2 (hu) N-oxidok mint 4-fenil-piridin-származékok előgyógyszerei, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0002208A2 (en) Use of sulphonamide derivatives for the preparation of pharmaceutical compositions potentiating glutamate receptor function
HUP0203136A2 (hu) Piperazinszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0301671A2 (hu) 4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk
HUP0401083A2 (hu) 4-Amino-6-fenil-pirrolo[2,3-d]pirimidin-származékok, ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására
HUP0302167A2 (hu) Metabotropikus glutamát receptor antagonista hatású kinolinszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
HUP0401339A2 (hu) Új 4-anilino-3-kinolinkarboxamidok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0402225A2 (hu) Makrolid-vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
CA2401229A1 (en) Aryl fused azapolycyclic compounds
HUP0301272A2 (hu) 4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
MXPA01004256A (es) N-arilamidas del acido antranilico y del acido tioantranilico.
HUP0302480A2 (hu) Piridinonszármazékok ateroszklerózis kezelésére, eljárás ezek előállítására és ezeket tartalmazó gyógyszerkészítmények
HUP0300527A2 (hu) Pirrolopirimidinon-származékok, a vegyületek előállítása és alkalmazása
HUP0301514A2 (hu) Benzimidazol származékok, elżállításuk és ezeket tartalmazó gyógyszerkészítmények
DE69227088D1 (de) Verwendung von 1-(aminoalkyl)-3-Quinoxalin-2-on Derivaten zur Herstellung von neuroprotektiven Mitteln
HUP0003577A2 (hu) Tetrahidro-gamma-karbolinok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
HUP0201315A2 (hu) 4-Fenil-pirimidin-származékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények
HK1115728A1 (en) Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same
CA2366205A1 (en) Biphenyl derivatives
YU39503A (sh) Derivati pirimidina
WO2005000840A8 (en) Substituted diketopiperazines and their use as oxytocin antagonists
HUP0002335A2 (hu) 2,3-Dihidrofuro[3,2-b]piridin-származékok, eljárás a vegyületek előállítására és gyógyászati alkalmazásuk
HUP0201024A2 (hu) Izoindoloindolon-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
NZ520155A (en) Thienopyridine derivatives, their production and use
HUP0003856A2 (hu) 6-Pirrolidin-2-ilpirindin-származékok, eljárás előállításukra és gyógyászati alkalmazásuk